Literature DB >> 17660820

C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy.

Anna Richards1, Arn M J M van den Maagdenberg, Joanna C Jen, David Kavanagh, Paula Bertram, Dirk Spitzer, M Kathryn Liszewski, Maria-Louise Barilla-Labarca, Gisela M Terwindt, Yumi Kasai, Mike McLellan, Mark Gilbert Grand, Kaate R J Vanmolkot, Boukje de Vries, Jijun Wan, Michael J Kane, Hafsa Mamsa, Ruth Schäfer, Anine H Stam, Joost Haan, Paulus T V M de Jong, Caroline W Storimans, Mary J van Schooneveld, Jendo A Oosterhuis, Andreas Gschwendter, Martin Dichgans, Katya E Kotschet, Suzanne Hodgkinson, Todd A Hardy, Martin B Delatycki, Rula A Hajj-Ali, Parul H Kothari, Stanley F Nelson, Rune R Frants, Robert W Baloh, Michel D Ferrari, John P Atkinson.   

Abstract

Autosomal dominant retinal vasculopathy with cerebral leukodystrophy is a microvascular endotheliopathy with middle-age onset. In nine families, we identified heterozygous C-terminal frameshift mutations in TREX1, which encodes a 3'-5' exonuclease. These truncated proteins retain exonuclease activity but lose normal perinuclear localization. These data have implications for the maintenance of vascular integrity in the degenerative cerebral microangiopathies leading to stroke and dementias.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17660820     DOI: 10.1038/ng2082

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  132 in total

1.  The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.

Authors:  Clinton D Orebaugh; Jason M Fye; Scott Harvey; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort.

Authors:  B Namjou; P H Kothari; J A Kelly; S B Glenn; J O Ojwang; A Adler; M E Alarcón-Riquelme; C J Gallant; S A Boackle; L A Criswell; R P Kimberly; E Brown; J Edberg; A M Stevens; C O Jacob; B P Tsao; G S Gilkeson; D L Kamen; J T Merrill; M Petri; R R Goldman; L M Vila; J-M Anaya; T B Niewold; J Martin; B A Pons-Estel; J M Sabio; J L Callejas; T J Vyse; S-C Bae; F W Perrino; B I Freedman; R H Scofield; K L Moser; P M Gaffney; J A James; C D Langefeld; K M Kaufman; J B Harley; J P Atkinson
Journal:  Genes Immun       Date:  2011-01-27       Impact factor: 2.676

3.  Defects in DNA degradation revealed in crystal structures of TREX1 exonuclease mutations linked to autoimmune disease.

Authors:  Suzanna L Bailey; Scott Harvey; Fred W Perrino; Thomas Hollis
Journal:  DNA Repair (Amst)       Date:  2011-11-08

Review 4.  The role of DNA exonucleases in protecting genome stability and their impact on ageing.

Authors:  Penelope A Mason; Lynne S Cox
Journal:  Age (Dordr)       Date:  2011-09-23

5.  Reconciling neuroimaging and clinical findings in Aicardi-Goutières syndrome: an autoimmune-mediated encephalopathy.

Authors:  G Ramantani; P Niggemann; T Bast; M A Lee-Kirsch
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-25       Impact factor: 3.825

6.  Evolution of a tumor-like lesion in cerebroretinal vasculopathy and TREX1 mutation.

Authors:  F J Mateen; K Krecke; B R Younge; A L Ford; A Shaikh; P H Kothari; J P Atkinson
Journal:  Neurology       Date:  2010-09-28       Impact factor: 9.910

Review 7.  Migraine and small vessel diseases.

Authors:  E Agostoni; A Rigamonti
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 8.  Translating nucleic acid-sensing pathways into therapies.

Authors:  Tobias Junt; Winfried Barchet
Journal:  Nat Rev Immunol       Date:  2015-08-21       Impact factor: 53.106

9.  A 44-year-old man with eye, kidney, and brain dysfunction.

Authors:  Ivana Vodopivec; Derek H Oakley; Cory A Perugino; Nagagopal Venna; E Tessa Hedley-Whyte; John H Stone
Journal:  Ann Neurol       Date:  2016-03-07       Impact factor: 10.422

Review 10.  [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].

Authors:  C Günther; F Schmidt; N König; M A Lee-Kirsch
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.